HER2 exon 20 insertions; EGFR exon 20 insertions

Class

Oral tyrosine kinase inhibitor selective for HER2/EGFR exon 20 insertion mutants

Pathway

HER2/EGFR exon20ins-driven signaling inhibition, wild-type EGFR sparing

HER2 and EGFR are related receptor tyrosine kinases that sit on the cell surface and, once activated, drive intracellular signaling pathways controlling cell growth and survival. In a subset of cancers, insertion mutations in exon 20 of either gene cause the kinase domain to become locked in an active state, generating continuous growth signaling independent of the normal ligand-binding trigger. These exon 20 insertions differ structurally from more common EGFR mutations, and this difference means that earlier-generation EGFR-targeted therapies, which were designed around those other mutations, generally interact poorly with exon 20-mutant kinases while still binding normal (wild-type) EGFR in healthy tissue. That mismatch produces limited tumor benefit alongside the same toxicities from wild-type EGFR inhibition seen in the skin and gut. An inhibitor engineered specifically for the exon 20 insertion conformation, in both HER2 and EGFR, aims to shut down the mutant-driven signaling responsible for tumor growth while leaving normal EGFR activity relatively undisturbed. Because HER2 and EGFR exon 20 insertions produce structurally similar alterations, one compound can potentially address both mutation types, which matters in cancers, particularly non-small cell lung cancer, where either gene may carry the driver mutation. This mechanism broadly matters wherever exon 20 insertion-driven signaling underlies tumor proliferation.